Clinical Trial Search

Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750

Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants

Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants

Primary: Skin Carotenoid Levels in Subjects With History of Squamous Cell Carcinoma Versus Control Subjects — 27,635; 31,219 Raman spectroscopy intensity counts — p=0.31

Primary: Overall Response Rate — 3 Participants

Primary: Cure Rate — 751 lesions

Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events

Primary: Number of Participants With Adverse Events — 10; 4; 1; 20 Participants

Primary: Number of Control and Intervention Participants on Skin Self-examination Performance at Follow-up 1 Month After Intervention — 34; 8 Participants

Primary: Early Progression Rate — 31.8 percentage of participants

Primary: Overall Response Rate — 11; 1; 10 Participants — p=0.0005

Primary: Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review — 40 Participants

Primary: Incidence of SCC — 3.1; 0.4 percentage of subjects

Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants

Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93

Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors

Primary: Number of Participants With Complete Response — 9; 5; 7; 9 Participants

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Objective Response Rate (Complete Response and Partial Response) — 0; 0 percentage of patients

Primary: Ki67 Tumor Proliferation Biomarker — 18; 0; -19; 13 Mean percent change — p=0.04

Primary: Percentage of Patients Who Complete Neoadjuvant Therapy and Were Eligible for Curative Surgical Resection — 16 Participants

Primary: Response (CR or PR), Stable Disease (SD), and Progressive Disease (PD) Rates — 6.81; 18.18; 75.00 percentage of participants

Primary: Number of Participants With Sustained Clearance Rate of Superficial Basal Cell Carcinoma (sBCC) — 119 participants

Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions

Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants

Primary: Tumor Clearance — 2; 2; 5 Participants

Primary: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy — 53.3; 53.7 Months — p=0.07243

Primary: Overall Response Rate (ORR) by Independent Central Review — 50.8; 44.9; 46.4; 61.9 percentage of participants

Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale

Primary: Objective Response Rate (ORR) — 35.2; 51.9 Percentage of participants